PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26846333-1 2016 BACKGROUND: Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin. roxadustat 12-22 erythropoietin Homo sapiens 157-171 34497233-7 2021 Sirolimus and roxadustat may be effective for relapsed/refractory PRCA with renal insufficiency and anti-erythropoietin antibody-mediated PRCA, respectively. roxadustat 14-24 erythropoietin Homo sapiens 105-119 26238121-12 2015 CONCLUSIONS: Roxadustat transiently and moderately increased endogenous erythropoietin and reduced hepcidin. roxadustat 13-23 erythropoietin Homo sapiens 72-86 34128578-0 2021 Roxadustat on anti-erythropoietin antibody-related pure red cell aplasia in the patient with end-stage renal disease. roxadustat 0-10 erythropoietin Homo sapiens 19-33 34128578-3 2021 Here, we present successful treatment of anti-EPO PRCA with roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor. roxadustat 60-70 erythropoietin Homo sapiens 46-49 34128578-11 2021 All in all, this case reveals the potential effect of roxadustat on anti-EPO PRCA. roxadustat 54-64 erythropoietin Homo sapiens 73-76 34500449-0 2022 Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis. roxadustat 0-10 erythropoietin Homo sapiens 20-34 34500449-7 2022 After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. roxadustat 18-28 erythropoietin Homo sapiens 49-52 34500449-8 2022 The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy. roxadustat 25-35 erythropoietin Homo sapiens 76-79 34756787-1 2021 OBJECTIVES: The present study aimed to explore the efficacy and safety of roxadustat in patients with renal anemia and erythropoietin (EPO) hyporesponsive who are receiving continuous ambulatory peritoneal dialysis (CAPD). roxadustat 74-84 erythropoietin Homo sapiens 119-133 34756787-1 2021 OBJECTIVES: The present study aimed to explore the efficacy and safety of roxadustat in patients with renal anemia and erythropoietin (EPO) hyporesponsive who are receiving continuous ambulatory peritoneal dialysis (CAPD). roxadustat 74-84 erythropoietin Homo sapiens 135-138 34756787-18 2021 CONCLUSIONS: In patients with EPO hyporesponsiveness on CAPD, roxadustat can efficiently and safely improve anemia and nutritional status without promoting inflammation. roxadustat 62-72 erythropoietin Homo sapiens 30-33 34754441-0 2021 Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia. roxadustat 0-10 erythropoietin Homo sapiens 64-78 35114188-2 2022 Roxadustat is one of the first oral medicines inducing EPO production in patients with renal anemia by activating hypoxia-inducible factors (HIFs), which are activators of EPO gene expression. roxadustat 0-10 erythropoietin Homo sapiens 55-58 35361724-2 2022 Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis by increasing endogenous erythropoietin and iron availability. roxadustat 0-10 erythropoietin Homo sapiens 126-140 35114188-2 2022 Roxadustat is one of the first oral medicines inducing EPO production in patients with renal anemia by activating hypoxia-inducible factors (HIFs), which are activators of EPO gene expression. roxadustat 0-10 erythropoietin Homo sapiens 172-175 35114188-3 2022 In this study, to develop prodrugs of roxadustat with improved permeability through cell membrane, we investigated the effects of 8 types of esterification on the pharmacokinetics and bioactivity of roxadustat using Hep3B hepatoma cells that HIF-dependently produce EPO. roxadustat 199-209 erythropoietin Homo sapiens 266-269 35114188-5 2022 Esterification prolonged the effective duration of roxadustat with respect to EPO gene induction and HIF activation in cells transiently exposed to the compounds. roxadustat 51-61 erythropoietin Homo sapiens 78-81 33853432-0 2021 Successful application of roxadustat in the treatment of patients with anti-erythropoietin antibody-mediated renal anaemia: a case report and literature review. roxadustat 26-36 erythropoietin Homo sapiens 76-90 34021853-0 2021 Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation. roxadustat 0-10 erythropoietin Homo sapiens 38-52 34021853-2 2021 Roxadustat reversibly binds and inhibits hypoxia-inducible factor-prolyl hydroxylase (HIF-PHD), resulting in increased endogenous EPO which stimulates erythropoiesis, theoretically has an advantage over exogenous EPO in anti-anemia therapy. roxadustat 0-10 erythropoietin Homo sapiens 130-133 34021853-2 2021 Roxadustat reversibly binds and inhibits hypoxia-inducible factor-prolyl hydroxylase (HIF-PHD), resulting in increased endogenous EPO which stimulates erythropoiesis, theoretically has an advantage over exogenous EPO in anti-anemia therapy. roxadustat 0-10 erythropoietin Homo sapiens 213-216 34021853-14 2021 Significant anti-anemia effects could be achieved in most patients with erythropoietin hypo-responsiveness after treatment with roxadustat, accompanied by relatively mild and rare adverse reactions. roxadustat 128-138 erythropoietin Homo sapiens 72-86 33475252-10 2021 Phase 3 trials of small molecule inhibitors of the PHD enzymes (hypoxia inducible factor-prolyl hydroxylase inhibitors [HIF-PHIs]), such as Roxadustat, have shown improved iron metabolism and increased circulating Epo levels in a titratable manner, avoiding the supraphysiologic increases that often accompany intravenous EPO therapy. roxadustat 140-150 erythropoietin Homo sapiens 214-217 33475252-10 2021 Phase 3 trials of small molecule inhibitors of the PHD enzymes (hypoxia inducible factor-prolyl hydroxylase inhibitors [HIF-PHIs]), such as Roxadustat, have shown improved iron metabolism and increased circulating Epo levels in a titratable manner, avoiding the supraphysiologic increases that often accompany intravenous EPO therapy. roxadustat 140-150 erythropoietin Homo sapiens 322-325 33853432-8 2021 This current case report demonstrates that roxadustat can be used to successfully treat anti-EPO antibody-mediated renal anaemia without the use of steroid-based immunosuppressants. roxadustat 43-53 erythropoietin Homo sapiens 93-96 32940725-0 2021 Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia. roxadustat 23-33 erythropoietin Homo sapiens 52-66 32603526-7 2020 Roxadustat induced transient elevations of endogenous erythropoietin that peaked between 7 and 14 hours after dosing and returned to baseline by 48 hours after dosing. roxadustat 0-10 erythropoietin Homo sapiens 54-68 33344604-0 2020 Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report. roxadustat 0-10 erythropoietin Homo sapiens 28-42 33063127-0 2021 Correction to: Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia. roxadustat 38-48 erythropoietin Homo sapiens 67-81 32856389-6 2020 Roxadustat is a new type of drug for the treatment of anaemia, and it can stimulate endogenous EPO within or near the physiologic range and increase haemoglobin levels. roxadustat 0-10 erythropoietin Homo sapiens 95-98 31340116-14 2019 Roxadustat was associated with a mean reduction in hepcidin of 30.2 ng per milliliter (95% CI, -64.8 to -13.6), as compared with 2.3 ng per milliliter (95% CI, -51.6 to 6.2) in the epoetin alfa group. roxadustat 0-10 erythropoietin Homo sapiens 181-188 32380083-2 2020 Prolyl hydroxylase (PHD) inhibitors, such as roxadustat, can stabilize hypoxia-inducible factor (HIF)-2alpha and induce erythropoietin (EPO) production under normal conditions. roxadustat 45-55 erythropoietin Homo sapiens 120-134 32380083-2 2020 Prolyl hydroxylase (PHD) inhibitors, such as roxadustat, can stabilize hypoxia-inducible factor (HIF)-2alpha and induce erythropoietin (EPO) production under normal conditions. roxadustat 45-55 erythropoietin Homo sapiens 136-139 32309288-8 2020 On the one hand, roxadustat could increase endogenous erythropoietin (EPO) levels within or near physiological range in a titratable manner by inducing HIF pathway activation transiently. roxadustat 17-27 erythropoietin Homo sapiens 54-68 32309288-8 2020 On the one hand, roxadustat could increase endogenous erythropoietin (EPO) levels within or near physiological range in a titratable manner by inducing HIF pathway activation transiently. roxadustat 17-27 erythropoietin Homo sapiens 70-73 32309288-13 2020 Roxadustat corrects anemia of CKD patients through multiple pathways, beyond elevating EPO levels within physiological range, and also by handling iron metabolism (particularly decreasing the hepcidin levels). roxadustat 0-10 erythropoietin Homo sapiens 87-90 29254377-8 2018 Given that the peaks of endogenous EPO are much lower than those observed with traditional ESA, it is possible to speculate the roxadustat (and more in general PHD inhibitors) will be safer than ESA on cardiovascular safety end-points. roxadustat 128-138 erythropoietin Homo sapiens 35-38